This padding only appears when menu bar covers the content below (browser width 1199px)
We test the safety of chemicals for use in our everyday lives
What we do
We use an alternative to animal models, C. elegans, to test chemicals for neurotoxicity, developmental neuro toxicity, and developmental and reproductive toxicity. Our innovative high-throughput platform provides cost effective and rapid in vivo testing.
Screening services OR Toxicology OR Toxicology testing
Protect public health with early identification of toxic environmental chemicals
Help industries reduce animal use while meeting regulatory compliance
Evaluate industrial chemicals that require further in vivo testing
Why C. elegans?
Click here to find out more (Create page?)
Newormics awarded SBIR Phase II grant from NIMH
Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
Newormics Announces Intent to Grant Utility Patent on the vivoChip by the European Patent Office
Newormics LLC, a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering the vivoChip® technology, the device design and use for C. elegans studies.